Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2176846
Abstract: ABSTRACT Introduction Cholangiocarcinoma (CCA) is an uncommon malignancy originating from epithelial cells of the biliary tract. Regardless of the site of origin within the biliary tree, CCAs are generally aggressive with a poor survival. Surgical… read more here.
Keywords: inhibitors cholangiocarcinoma; therapy; idh inhibitors; therapy developments ... See more keywords